IPWatchdogOpinion

The DOJ Understands Royalty-Free Licensing is Far from Free

Is it the case that “royalty-free” applied to standard-essential patents (SEPs) is FRAND (fair, reasonable and ...

Free market groups warn Trump: British patent plan would weaken US tech edge, empower China

President Donald Trump faced pressure from 26 conservative groups to reject U.K. intellectual property reforms they said ...
KTLA

Arecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292

AT278 (500U/mL) is the only ultra-concentrated and ultra-rapid acting insulin in development designed to enable the next generation of longer-wear and miniaturised automated insulin delivery (AID) ...
Business Wire

Pharmaceutical and Biotechnology Royalty Rates Report and Directory 2024: Technology Licensed, License Fees, Upfront and Milestone Payments for Deals Signed Since 2020 ...

DUBLIN--(BUSINESS WIRE)--The "Royalty Rates in Pharmaceutical and Biotechnology Deals" report has been added to ResearchAndMarkets.com's offering. Royalty Rates in Pharmaceutical and Biotechnology ...
The Globe and Mail

AbTherx and Mosaic Biosciences Forge Exclusive Partnership to Provide Milestone and Royalty-Free Access to AbTherx's Premier Human Antibody Discovery Technology

End-to-end program integration from in vivodiscovery through candidate selection, creating a single, premium path to the clinic MOUNTAIN VIEW, CA AND BOULDER CO / ACCESS Newswire / September 17, 2025 ...
Yahoo Finance

Arecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292

Cambridge, UK, 25 September 2025: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases, has signed ...